Advertisement

Preparation Of Radionuclides And Their Measurement By High Resolution γ-Spectrometry, β-Spectrometry And High Resolution α-Spectrometry

  • Flavia Groppi
  • L. Mauro Bonardi
  • Luigigini Bonardi
  • Zeev B. Alfassi
Conference paper
Part of the NATO Science for Peace and Security Series B: Physics and Biophysics book series (NAPSB)

The use of High Specific Activity Radionuclides HSARNs, obtained by either proton, deuteron or alpha cyclotron irradiation, followed by selective radiochemical separation from the irradiated target in No Carrier Added (NCA) form, is a powerful analytical tool. The main applications of these radionuclides are to medical dignosis and therapy in addition to toxicological, environmental and industrial studies. These NCA radionuclides and their Specific Activity (AS) can reach values close to the theoretical “carrier-free ” one AS(CF). The “real ” AS(NCA) must by measured by either analytical or/and radioanalytical techniques. The “accurate ” knowledge of behavior of cross-sections of each reaction, as a function of beam energy (excitation functions) is mandatory. The minimization of Isotopic Dilution Factor is achieved also. Some examples of production and radioanalytical quality control methods for HSARNs are presented.

Keywords

γ-spectrometry α-spectrometry β-spectrometry radionuclide measurements HSARNs 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bonardi M et al. (2002) High specific activity radioactive tracers: a powerful tool for studying very low level and long term exposure to different chemical forms of both essential and toxic elements. Microchem J 73:153–166CrossRefGoogle Scholar
  2. 2.
    Bonardi M L et al. (2004) Cyclotron production and quality control of “High Specific Activity ” radionuclides in “No Carrier Added ” form for radioanalytical applications in the life sciences. J Radioanal Nucl Chem 259:415–419CrossRefGoogle Scholar
  3. 3.
    Bonardi M et al. (1988) Fundamental parameters for the optimization of yield and radionuclidic purity of accelerator produced radioisotopes. Part I: thin-target excitation functions. Phys Med 1:23–46Google Scholar
  4. 4.
    Bonardi M et al. (1988) Fundamental parameters for the optimization of yield and radionulidic purity of accelerator produced radioisotopes. Part II: beam control and monitoring. Phys Med 2:83–101Google Scholar
  5. 5.
    Bonardi M et al. (1995) Irradiation methods for production of high specific activity radionuclides in No Carrier Added Form. J Radioanal Nucl Chem 195:227–236CrossRefGoogle Scholar
  6. 6.
    Birattari C et al. (2001) Review of cyclotron production and quality control of high specific activity radionuclides for biomedical, biological, industrial and environmental applications at INFN-LASA. Proceeding International Congress on Cyclotrons and Their Applications, Cyclotron2001, East Lansing, MI, May 2001. American Institute of Physics, Melville, NYGoogle Scholar
  7. 7.
    Bonardi M L et al. (2003) Thin-target excitation functions: a powerful tool for optimising yield, specific activity and radionuclidic purity of accelerator-produced radionuclides. Czech J Phys 53:A393–A403CrossRefGoogle Scholar
  8. 8.
    Bonardi M (1988) The contribution to nuclear data for medical radioisotope production from the Milan Cyclotron Laboratory, IAEA Consultant's Meeting on “Nuclear Data Requirements for Medical Radioisotope Production ”, Tokyo, April 1987, IAEA Document, INDC(NDS)-195/GZ, IAEA, Vienna, Jan. 1988, pp. 98–112Google Scholar
  9. 9.
    IAEA-TECDOC-1211 Charged-particle cross-section database for medical radioisotope production. Co-ordinated Research Project (1995–1999). IAEA Vienna, Austria, May 2001 Available online at: http://www-nds.iaea.org/medical/
  10. 10.
    Menapace E et al. (2004) Experimental results and model calculation of excitation functions relevant to the production of specific radioisotopes for metabolic radiotherapy and for PET. Radiat Phys Chem 71:943–945CrossRefGoogle Scholar
  11. 11.
    Groppi F et al. (2005) The use of liquid scintillation counting as a very sensitive radioanalytical tool for the determination of alpha, beta and electron emitting impurities in radiopharmaceutical compounds. J Radioanal Nucl Chem 263:521–525Google Scholar
  12. 12.
    Bonardi M L et al. (2005) Cross section studies on 64Cu with zinc target in the proton energy range from 141 down to 31 MeV. J Radioanal Nucl Chem 264:101–105CrossRefGoogle Scholar
  13. 13.
    Abbas K et al. (2006) Cyclotron production of 64Cu by deuteron irradiation of 64Zn. Appl Radiat Isotopes 64:1001–1005CrossRefGoogle Scholar
  14. 14.
    Groppi F et al. (2005) Optimisation study of alpha-cyclotron production of At-211/Po-211g for high-LET metabolic radiotherapy purposes. Appl Radiat Isotopes 63:621–631CrossRefGoogle Scholar
  15. 15.
    Groppi F et al. (2006) Results on accelerator production of innovative radionuclides for metabolic radiotherapy and PET and on related nuclear data. Nucl Instrum Meth A 562:1072–1075CrossRefGoogle Scholar
  16. 16.
    Morzenti S et al. (2008) Alpha-cyclotron production of 211At/211gPo by 209Bi(α, 2n) reaction. J Radioanal Nucl Chem 276:843–847CrossRefGoogle Scholar
  17. 17.
    Zona C et al. (2008) Wet-chemistry method for the separation of no-carrier-added 211At/211gPo from alpha cyclotron irradiated 209Bi target. J Radioanal Nucl Chem 276:819–824CrossRefGoogle Scholar
  18. 18.
    Ridone S et al. (2004) Radioanalytical quality control on beta-emitting [186gRe]- and [153Sm]-radiopharmaceutical compounds for bone metastases pain palliation. World J Nucl Med 3:241Google Scholar
  19. 19.
    Persico E et al. (2006) Proton and deuteron cyclotron production studies of high specific activity 186gRe for radiotherapy. Technetium, Rhenium and other metals in Chemistry and Nuclear Medicine, SGE Editoriali, Padova, Italia, 7:613–614Google Scholar
  20. 20.
    Groppi F et al. (2005) Accurate determination of radionuclidic purity and half-life of reactor produced Lu-177g for metabolic radioimmunotherapy, World SciCo Singapore, 710–714Google Scholar
  21. 21.
    Canella L et al. (2008) Accurate determination of radionuclidic purity of reactor produced 177gLu for metabolic radiotherapy. J Radioanal Nucl Chem 276:813–818CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V 2009

Authors and Affiliations

  • Flavia Groppi
    • 1
  • L. Mauro Bonardi
    • 1
  • Luigigini Bonardi
    • 1
  • Zeev B. Alfassi
    • 2
  1. 1.Radiochemistry Laboratory, via F.lli Cervi 201Universita degli Studi di Milano and INFN-Milano, LASASegrateItaly
  2. 2.Department of Nuclear EngineeringBen Gurion University of NegevBeer-ShevaIsrael

Personalised recommendations